Skip to main content
Clinical Trials/JPRN-UMIN000036560
JPRN-UMIN000036560
Recruiting
未知

The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM - The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM

ippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology0 sites30 target enrollmentMay 1, 2019
ConditionsAFLD/NASH

Overview

Phase
未知
Intervention
Not specified
Conditions
AFLD/NASH
Sponsor
ippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 1, 2019
End Date
March 31, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. pregnant woman or lactating mother 2\. poorly controlled heart failure 3\. poorly controlled hypertension or diabetes 4\. severe renal disorder 5\. decompensated liver cirrhosis 6\. other liver diseases, including autoimmune hepatitis, primary biliary cholangitis and alcoholic hepatitis, liver failure 7\. positive result for hepatitis C antibody, hepatitis B surface antigen and antibody to human immunodeficiency virus type\-1 8\. hypercarcemia 9\. hyperparathyroidism 10\. Judged by investigator not to be appropriate for inclusion in this study

Outcomes

Primary Outcomes

Not specified

Similar Trials